NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 92 filers reported holding NUVALENT INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,878,472 | +20.8% | 40,863 | +10.8% | 0.00% | – |
| Q2 2023 | $1,555,272 | -85.7% | 36,881 | -91.2% | 0.00% | -100.0% |
| Q1 2023 | $10,884,000 | +85607.5% | 417,204 | -2.2% | 0.00% | -50.0% |
| Q4 2022 | $12,699 | -99.8% | 426,426 | +0.1% | 0.00% | +100.0% |
| Q3 2022 | $8,282,000 | +38.7% | 426,091 | -3.3% | 0.00% | 0.0% |
| Q2 2022 | $5,973,000 | -2.8% | 440,452 | -0.5% | 0.00% | 0.0% |
| Q1 2022 | $6,147,000 | -17.6% | 442,575 | +13.0% | 0.00% | 0.0% |
| Q4 2021 | $7,457,000 | +7918.3% | 391,645 | +9445.3% | 0.00% | – |
| Q3 2021 | $93,000 | – | 4,103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
| Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
| COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
| Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
| Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
| Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
| Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
| Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |